WO2010131826A1 - 오스테오폰틴 억제제 스크리닝 방법 및 그에 따른 억제제 - Google Patents
오스테오폰틴 억제제 스크리닝 방법 및 그에 따른 억제제 Download PDFInfo
- Publication number
- WO2010131826A1 WO2010131826A1 PCT/KR2009/007114 KR2009007114W WO2010131826A1 WO 2010131826 A1 WO2010131826 A1 WO 2010131826A1 KR 2009007114 W KR2009007114 W KR 2009007114W WO 2010131826 A1 WO2010131826 A1 WO 2010131826A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- osteopontin
- screening
- formula
- inhibitor
- group
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
- C07C2602/28—Hydrogenated naphthalenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
- G01N2333/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis
Definitions
- the present invention relates to a method for screening an osteopontin inhibitor and an inhibitor obtained by the method.
- Osteopontin is produced in osteoclasts and osteoblasts and is known to play an important role in bone metabolism. Although not required for normal bone development in rats, it is involved in bone remodeling and sometimes serves as a defense against infection and injury. In addition, research has been reported to have the activity to promote the growth or metastasis of cancer cells. Osteopontin-free rats had less bone mineral density and less bone weakness (Hiroyuki Yoshitake et al., 1999, PNAS., 96: 8156-8160). Osteopontin functions normally in rats with symptoms of rheumatoid arthritis. The rats' symptoms gradually worsened, the joints swollen and cartilage destroyed.
- osteopontin-inhibiting arthritis did not progress and cartilage was not destroyed (Kenji Yumoto et al., 2002 PNAS., 99: 4556-4561).
- substances that inhibit the activity of osteopontin may be used to prevent and treat osteoporosis, rheumatoid arthritis and periodontal disease.
- Osteopontin is a glycoprotein with a mass of 44 kilodaltons, phosphorylated and acidified by serines and threonines. The feature is that it has a calcium binding motif, which may explain its ability to bind a lot of calcium (Giachelli, C. M et al., 1995 Trends Cardiovasc Med 3: 88-95). Osteopontin in the bone matrix promotes the attachment of osteoclasts to bone through matrix binding (Ross, F.P., et al., 1993 J. Biol. Chem 268: 9901-9907). Water-soluble osteopontin in osteoclasts regulates calcium levels, acts as a chemotactic agent and inhibits endothelial cell death (Khan SA., Et al., 2002 Mol Biol Cell 85: 728-736).
- Osteopontin has a domain containing RGD (arginine-glycine-asphatate), which interacts with cell surface integrins ( ⁇ v ⁇ 3, ⁇ v ⁇ 1, ⁇ v ⁇ 5) and is involved in cell adhesion, and the (SVVYGLR) sequence is integrin They interact with ( ⁇ 9 ⁇ 1, ⁇ 4 ⁇ 1) and are exposed to cleavage by thrombin.
- RGD arginine-glycine-asphatate
- ⁇ v ⁇ 3, a major integrin on the surface of osteoclasts, is usually expressed at low levels in the small intestine or vascular muscle cells, but is expressed at high levels in bones, inflamed areas, placenta, and infiltrated tumors, resulting in bone resorption of osteoclasts and activation of macrophages. It acts on angiogenesis.
- Osteopontin acts as an integrin ⁇ v ⁇ 3 ligand to increase bone resorption by osteoclasts and promotes osteoclast migration and is involved in early attachment (Ichiro Nakamura., Et al., 2007 J Bone Miner Metab) 25: 337-344).
- Osteoclasts are differentiated from hematopoietic stem cells (Boyle WJ., Et al., 2003 Nature 423: 337-42).
- osteoclasts were normally made but inhibited osteoclast differentiation in osteoclasts by RANKL in the differentiation of human osteoclasts with reduced osteopontin expression.
- osteopontin has been suggested as an important factor in the differentiation into osteoclasts in humans (Cathy J. Aitken., Et al., 2004 J. Cell. Biochem 93: 896-903).
- the present invention has been made in view of the above necessity, and an object of the present invention is to provide a method for screening an osteopontin inhibitor.
- Another object of the present invention is to provide an osteopontin inhibitor.
- Another object of the present invention is to provide a use for the treatment of diseases of osteopontin inhibitors.
- the present invention includes the steps of: a) searching for a starting material for protein chip screening by performing a molecular docking simulation of the entire library compound file; b) preparing a mixture by mixing the found starting material with Osteopontin and fluorescently labeled Osteopontin; c) adding the mixture onto an integrin ⁇ v ⁇ 3 receptor immobilized on a protein chip; and d) analyzing the binding degree.
- the above screening method of the present invention is called 'Integrated Drug Discovery Platform (IDDP) technology'.
- IDDP Integrated Drug Discovery Platform
- This integrated drug screening-based technology is InnoPharma Screen's unique drug development system, which integrates structure-based screening (in silico), protein chip-based screening (HTS), and / or cell-based assays. It is a standard platform for new drug development that can find the most effective drug candidates at the minimum cost in the shortest time from target discovery to optimization of lead substance.
- the search algorithm for the docking calculation is preferably an alpha triangle method, but is not limited thereto.
- the fluorescent material is Cy3 (green), Cy5 (red), FITC (green), Alexa (BODIPY), Rhodamine, and Q-dot ( dot) is preferably at least one fluorescent material selected from the group consisting of, and the fluorescent material is more preferably Cy5, but is not limited thereto.
- the present invention provides an osteopontin inhibitor comprising at least one compound selected from the group consisting of Formulas 1 to 3, derivatives thereof or salts thereof.
- the present invention provides a composition for treating or preventing osteoporosis, arthritis, or periodontal disease comprising at least one compound selected from the group consisting of Formula 1 to 3, its derivatives or salts thereof as an active ingredient.
- the term "derivative” means a similar compound obtained by chemically changing a part of a compound, for example, a compound in which a hydrogen atom or a specific atomic group in the compound is substituted by another atom or atomic group.
- Compounds of the invention are osteopontin inhibitors, and compounds of the invention may be used to inhibit osteopontin activity.
- the present invention can be used for the treatment of diseases in which osteopontin inhibition is useful, as well as pharmaceutical compounds containing the compounds or salts thereof, as well as compounds of one of the compounds of formulas 1 to 3 Can be.
- Such diseases include, for example, inflammation of joints, including arthritis and rheumatoid arthritis, as well as other joint diseases such as rheumatoid spondylitis and osteoarthritis. Further applicability is the treatment of osteoporosis, periodontal disease and the like.
- auxiliaries, carriers and additives are used in addition to effective amounts of the compounds of the invention or salts thereof.
- the dosage of active ingredient may vary depending on the manner in which it is administered, the age, weight of the patient, the nature and severity of the disease to be treated and similar factors.
- the daily dose may be administered in a single dose administered once daily, or may be divided into two or more doses per day, typically 0.001 to 100 mg.
- parenteral, intravenous, transdermal, topical, inhaled and intranasal preparations are the preferred dosage forms.
- compositions can be used, for example tablets, coated tablets, capsules, dispersible powders, granules, aqueous solutions, aqueous or oily suspensions, syrups, solutions or drops.
- Drugs in solid form include inert ingredients and carriers such as calcium carbonate, calcium phosphate, sodium phosphate, lactose, starch, mannitol, alginate, gelatin, guar gum, magnesium or aluminum stearate, methylcellulose, talc, high dispersion May contain silica, silicone oils, high molecular weight fatty acids such as stearic acid, gelatin, agar agar, vegetable or animal fats and oils, and solid high molecular weight polymers such as polyethylene glycols. Suitable formulations may optionally contain additional flavoring and / or sweetening agents.
- inert ingredients and carriers such as calcium carbonate, calcium phosphate, sodium phosphate, lactose, starch, mannitol, alginate, gelatin, guar gum, magnesium or aluminum stearate, methylcellulose, talc, high dispersion May contain silica, silicone oils, high molecular weight fatty acids such as stearic acid, gelatin, a
- Drugs in liquid form may be sterilized and / or optionally with preservatives, stabilizers, wetting agents, permeants, emulsifiers, diffusion agents, solubilizers, salts, sugars or sugar alcohols, and / or viscosity modifiers for osmotic pressure control or buffering purposes. It may contain the same adjuvant.
- additives examples include tartrate and citrate buffer, ethanol, complexing agents such as ethylenediaminetetraacetic acid and its nontoxic salts.
- high molecular weight polymers such as liquid polyethylene oxide, microcrystalline cellulose (such as carboxymethylcellulose), polyvinylpyrrolidone, dextran or gelatin are contemplated.
- Solid carrier materials include, for example, starch, lactose, mannitol, methylcellulose, talc, highly dispersed silica, high molecular weight fatty acids such as stearic acid, gelatin, agar agar, calcium phosphate, magnesium stearate, animal and vegetable fats.
- solid high molecular weight polymers such as polyethylene glycol.
- Parenteral or topical oily suspensions are vegetable, synthetic or semisynthetic oils, for example monohydric or trihydric alcohols having 1 to 6 carbon atoms in each case (e.g. methanol, ethanol, propanol, butanol, pentanol Or fatty acids (e.g., palmitic acid, lauric acid, tridecyl acid, margaric acid, stearic acid, arachidic acid, myristic acid, behenic acid, pentadecyl acid, esterified with isomers, glycols or glycerol thereof) , Linoleic acid, elideic acid, brasidic acid, erucic acid or oleic acid) chains may contain liquid fatty esters having from 8 to 22 carbon atoms.
- monohydric or trihydric alcohols having 1 to 6 carbon atoms in each case
- fatty acids e.g., palmitic acid, lauric acid, tridecyl acid, mar
- Such fatty esters include, for example, commercially available migliol, isopropyl myristate, isopropyl palmitate, isopropyl stearate, PEG 6-capric acid of saturated fatty alcohols, caprylic / capric acid esters, Polyoxyethylene glycerol trioleate, ethyl oleate, waxy fatty esters (e.g. synthetic duck rump gland fat), isopropyl ester of coconut oil fatty acid, oleyl oleate, decyl oleate, ethyl lactate , Dibutyl phthalate, diisopropyl adipate, fatty acid esters of polyols, and the like.
- migliol isopropyl myristate, isopropyl palmitate, isopropyl stearate
- PEG 6-capric acid of saturated fatty alcohols caprylic / capric acid esters
- Silicone oils or fatty alcohols of different viscosities eg isotridecyl alcohol, 2-octyldodecanol, cetyl stearyl alcohol or oleyl alcohol
- fatty acids eg oleic acid
- vegetable oils such as castor oil, almond oil, olive oil, sesame oil, cottonseed oil, peanut oil or soybean oil may be used.
- a gel forming agent and a solubilizer water or a solvent miscible with water are contemplated.
- cellulose ethers which can be dissolved or swelled in water as well as in organic solvents such as hydroxypropylmethylcellulose, methylcellulose, ethylcellulose or soluble starch can be used.
- ionic macromolecules can be used herein, for example, sodium carboxymethylcellulose, polyacrylic acid, polymethacrylic acid and salts thereof, propylene glycol know as sodium avelopectin semiglycolate, alginic acid or sodium salt. Nate, gum arabic, xanthan rubber, guar rubber or carrageen rubber can be used.
- Further formulation aids may include glycerin, paraffins of different viscosities, triethanolamine, collagen, allantoin, novantisolic acid.
- glycerin paraffins of different viscosities
- triethanolamine collagen
- allantoin novantisolic acid.
- surfactants such as cetyl alcohol, lecithin, glycerin monostearate, polyoxyethylene stearate, alkylphenol polyglycol ethers, cetyltrimethylammonium chloride or monoalkyl or dialkyl polyglycol ether orthophosphoric acid monoethanolamine salts, Emulsifiers or wetting agents are used.
- stabilizers for emulsion stabilization e.g. montmorillonite or colloidal silica
- stabilizers for the degradation of active substances such as antioxidants (e.g. tocopherol or butylhydroxyanisole), or preservatives ( Eg p-hydroxybenzoate ester) may also be required.
- Formulations for parenteral administration may be in the form of individual dosage units such as ampoules or vials.
- solutions of the active ingredient are used, in particular aqueous solutions and, inter alia, isotonic solutions, but suspensions are also used.
- injectable forms can be used as finished preparations or can be prepared immediately before use by mixing the active compound, such as a lyophilisate, with another solid carrier material, the desired solvent or suspending agent.
- Intranasal preparations may be present in aqueous or oily solutions or in aqueous or oily suspensions. They may be present as lyophilisates prepared with a suitable solvent or suspending agent prior to use.
- the process of preparing the formulation, filling it into a container and sealing it is carried out under conventional antibacterial and sterile conditions.
- the compounds of the present invention can be prepared by conventional methods of preparation well known in the art.
- the compounds of the present invention are substances screened in a natural compound library (40,000 species) sold by InterBioScreen (IBM) www.ibscreen.com, Russia, and InterBioScreen (IBM). ) Purchased from the company.
- IBM InterBioScreen
- Osteopontin is a glycoprotein that is abundant in the bone matrix and is involved in osteoclast differentiation and adhesion movement.
- the osteoclast is a cause of bone-related diseases such as osteoporosis, rheumatoid arthritis and periodontal disease.
- Substances that inhibit the activity of osteopontin can be developed as raw materials for the treatment of such bone-related diseases and medicines.
- a method of quickly and easily screening tens of thousands of compounds was needed. Substances discovered using virtual screening methods and protein chips could be developed as osteopontin inhibitors.
- the screening method of the present invention and a substance that inhibits the activity of osteopontin according to the present invention can be developed as a raw material for treating bone-related diseases and pharmaceuticals by inhibiting the differentiation and migration of osteoclasts.
- Table 1 is a virtual screening method of the osteopontin inhibitor and Table 1 shows the binding energy values of the 100 compounds having the best binding results as a result of the virtual screening.
- Figure 2 is a graph showing the results of experiments confirmed by the concentration of the binding by the interaction of osteopontin and integrin ⁇ v ⁇ 3,
- 3 is a representative image and a virtual image of binding experiments by interaction of osteopontin with integrin ⁇ v ⁇ 3 from a natural-derived compound library
- FIG. 8 is a graph quantifying the broken bone area of the In vivo Calvaria animal model from the results of FIG. 7.
- the software used for the virtual screening of FIG. 1 is a Molecular Operating Environment (MOE) program of the Chemical Computing Group.
- the search method used molecular docking simulation. The specific method is as follows. First, first order molecular docking simulations were performed for all 40,000 library compound files. The search algorithm for the docking calculation was performed using up to 500,000 structural change energy calculations for each ligand compound using the Alpha Triangle method. The method uses an algorithm that shapes the three points of the molecule into triangles and docks by determining whether they match another triangle of the receptor protein. The scoring method used the LondondG method to calculate up to 10 poses per ligand. There are three scoring methods supported by MOE: LondondG, AffinitydG, and AlphaHB. LondondG used in this calculation is as follows.
- the LondondG function uses parameters such as rotational / translation entropy change due to bonding, reduction of flexibility energy due to ligand binding, hydrogen bonding energy, metal ion ligation, and desolavtion energy difference.
- the second docking simulation was performed by selecting 5,000 compounds having excellent binding strength.
- the method used for the second docking simulation is basically the same as the method for the first docking simulation, and an energy minimization method is added.
- Energy minimization molecular dynamics calculations were performed for the docked ligand poses to explore the most stable ligand structure that can be derived from the binding structure.
- the calculated binding energy values were used as parameters of the binding force screening. Docking simulations for 5,000 compounds and 100 compounds with the best LondondG values, scores of energy minimization results, were selected and suggested as starting materials for protein chip screening (Table 1).
- Table 1 shows the binding energy values of the 100 compounds having the highest binding force as a result of the virtual screening.
- Integrin ⁇ v ⁇ 3 receptor microarray by spotting integrin ⁇ v ⁇ 3 (Chemicon, Temecula, Canada) on a ProteoChip TM (Proteogen Inc., Seoul, Korea) surface with a microarray (CM-1000; Proteogen, Inc., Seoul, Korea) (Integrin adhesion protein chip) was constructed.
- integrin ⁇ v ⁇ 3 100 ⁇ g / ml of integrin ⁇ v ⁇ 3 in phosphate-buffered saline (PBS) containing 10 mM ⁇ -octylthioglucopyranoside, 1 mM CaCl 2 , 1 mM MgCl 2 and 30% glycerol solution
- PBS phosphate-buffered saline
- the combined and remaining integrin ⁇ v ⁇ 3 was washed with phosphate-buffered saline containing 0.5% Tween-20 (0.5% PBST) and stored at 4 ° C. until use.
- the integrin ⁇ v ⁇ 3-osteopontin In order to examine the interaction of integrin ⁇ v ⁇ 3-osteopontin, the integrin ⁇ v ⁇ 3-attached protein chips prepared in Example 2 were blocked with 3% BSA for 1 hour and washed three times with PBST. The integrin microarray was then subjected to Cym 5 fluorescently labeled osteopontin at a concentration ranging from 10 ⁇ g / ml to 12 ng / ml to 10 mM ⁇ -octyl-thio-gluco-pyranoside ( ⁇ -octyl-thio-gluco- pyranoside), 1mM CaCl 2 , 1mM MgCl 2 , 0.2mM MnCl 2 and 30% glycerol solution in phosphate-buffered saline (PBS) diluted with spotted reaction.
- PBS phosphate-buffered saline
- FIG. 2 is a graph showing dose-response curves of integrin ⁇ v ⁇ 3-osteopontin interaction with fluorescence scan images showing integrin ⁇ v ⁇ 3-osteopontin interaction.
- FIG. 3B is a graph showing the relationship between the relative fluorescence intensity of the osteopontin spot and the log of Cy-5 fluorescently labeled fibronectin concentration.
- integrin ⁇ v ⁇ 3 was shown to work well with osteopontin labeled with Cy5. Among these, osteopontin showed a saturation reaction at about 1 ⁇ g / ml or more. As a result, it can be seen that the integrin ⁇ v ⁇ 3-attached protein chip is effective and suitable for the screening of binding inhibitors of the integrin ⁇ v ⁇ 3 and osteopontin.
- the natural product-derived compound library 50 mM
- osteopontin (Cy-5; Amersham Parmacia Biotech, Uppsala Sweden) were labeled with osteopontin and then obtained in Example 1.
- Phosphate-buffered saline solution containing 10 mM ⁇ -octyl-thio-gluco-pyranoside, 1 mM CaCl 2 , 1 mM MgCl 2 , 0.2 mM MnCl 2 and 30% glycerol solution ( diluted in phosphate-buffered saline (PBS).
- the integrin ⁇ v ⁇ 3-attached protein chips prepared in Example 2 were blocked with 3% BSA for 1 hour and washed three times with PBST. Then, using the microarray (CM-1000; Proteogen, Inc., Seoul, Korea) under the condition of 70% of 30 ° C., the mixed solution containing each of the above libraries and osteopontin was prepared. After spotting on the integrin ⁇ v ⁇ 3 receptor immobilized on, the cells were allowed to react for one hour. After washing with washing solution (0.0% PBST) was dried using nitrogen and the degree of inhibition of the library was measured by analyzing the degree of ligand binding in relative fluorescence intensity using a fluorescence laser scanner. As a result, a large number of libraries showed relatively low fluorescence intensities, demonstrating that the compound effectively inhibits the integrin ⁇ v ⁇ 3-osteopontin binding reaction (FIG. 3).
- Figure 3 is the result of experiments to determine whether the inhibition of the interaction of the integrin ⁇ v ⁇ 3 and osteopontin of the library.
- RGD amino acid sequence: GRGDSP
- the result is a single color, such as a color, but in this case it is difficult to see the fluorescence intensity easily, so the software of the device changes the color according to the fluorescence intensity.
- the fluorescence intensity is expressed in the order of white to red, orange, yellow, green and blue. 2, it can be seen that only the fluorescently labeled osteopontin was reacted with integrin ⁇ v ⁇ 3 and osteopontin in white or red color.
- the interaction of integrin ⁇ v ⁇ 3 with osteopontin is suppressed, and thus the fluorescence is shown as the lowest blue color because the osteopontin does not bind to integrin ⁇ v ⁇ 3.
- Example 3-3 Using the method used in Example 3-3, the three inhibitors (Fig. 5) discovered in Example 3-3 were diluted in concentrations from 100 mM to 2 times by concentration to 1 mM and treated with integrin ⁇ v ⁇ 3 fixed at a concentration of 100 mg / ml. IC 50 values that inhibit osteopontin binding labeled with Cy5 at a concentration of 1 mg / ml were determined (FIG. 4).
- Bone marrow cells harvested from 5 week old mice were placed in a 48-well plate and contained hM-CSF (R & D system Inc.), a macrophage differentiation factor, at a concentration of 30 ng / ml.
- hM-CSF R & D system Inc.
- a-MEM In differentiation medium
- the osteoclast differentiation factor, RANKL was expressed in Escherichia coli, purified, purified, and added at a concentration of 100 ng / ml, followed by culturing in osteoclasts under the same conditions. Cell differentiation was induced. After 4 days of incubation, the cells were fixed at room temperature for 15 minutes in 3.7% formaldehyde and washed twice with distilled water and then acetate, fastgar at the ratios described in the instructions of Acid Phosphatase, Leukocyte (TRAP) kitTM (Sigma Co.).
- TRAP Acid Phosphatase, Leukocyte
- Differentiated osteoclasts were stained by adding 200 ⁇ g / well of a dye solution prepared by mixing four fast gargnet GBC bases, naphthol AS-BI phosphate, sodium nitrite and tartrate for 37 to 20 minutes. 6, the osteopontin inhibitors IPS-02001, IPS-02002, IPS-02003 using the above experiment to analyze the inhibition of differentiation of osteoclasts. As a result, IPS-02001 and IPS-02002 showed excellent osteoclast differentiation inhibitory effect, but IPS-02003 showed no inhibitory effect.
- LPS (12.5 mg / kg) or RANKL (2 mg / kg) in the cranial cranial canal of 7-week-old mice to investigate the inhibitory effects of RANKL or LPS-induced bone destruction in real mice.
- Image-pro Plus4.5 Media Cybernetics, Inc. was used to analyze the degree of inhibition of bone destruction.
- Lipopolysaccharide (10 mg / kg), an inflammation-causing substance that destroys bone cells, is treated in the rat's head bones to artificially induce osteoporosis, and IPS-02001 (10 mg / kg) is treated to restore bone cell destruction.
- IPS-02001 confirmed the in vivo efficacy of inhibiting bone destruction caused by LPS (FIG. 7).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (8)
- a) 라이브러리 화합물 파일 전체에 대하여 분자 도킹 시뮬레이션을 실시하여 단백질 칩 스크리닝을 위한 시작물질을 탐색하는 단계;b) 상기 탐색된 시작물질을 오스페오폰틴과 형광물질 표지된 오스테오폰틴과 혼합하여 혼합물을 제조하는 단계;c) 상기 혼합물을 단백질 칩에 고정된 인테그린 αvβ3 수용체 위에 첨가하는 단계: 및d) 상기 결합 정도를 분석하는 단계를 포함하는 오스테오폰틴 억제제의 스크리닝 방법.
- 제 1항에 있어서, 상기 도킹 계산을 위한 검색 알고리즘은 알파 트라이앵글 방법을 사용한 것을 특징으로 하는 오스테오폰틴 억제제의 스크리닝 방법.
- 제 1항에 있어서, 상기 형광물질은 Cy3(그린), Cy5(레드), FITC(그린), 알렉사(Alexa), 보디피(BODIPY), 로다민(Rhodamine), 및 Q-도트(dot)로 구성된 군으로부터 선택된 하나 이상의 형광물질인 것을 특징으로 하는 오스테오폰틴 억제제의 스크리닝 방법.
- 제 3항에 있어서, 상기 형광물질은 Cy5인 것을 특징으로 하는 오스테오폰틴 억제제의 스크리닝 방법.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012510731A JP2012526983A (ja) | 2009-05-12 | 2009-12-01 | オステオポンチン抑制剤のスクリーニング方法及びそれによる抑制剤 |
EP09844700.6A EP2431738A4 (en) | 2009-05-12 | 2009-12-01 | SCREENING PROCESS FOR OSTEOPONTIN INHIBITOR AND INHIBITOR MANUFACTURED THEREWITH |
US13/296,049 US20120264942A1 (en) | 2009-05-12 | 2011-11-14 | Method for screening osteopontin inhibitor and inhibitor obtained from the method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20090041235 | 2009-05-12 | ||
KR10-2009-0041235 | 2009-05-12 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/296,049 Continuation US20120264942A1 (en) | 2009-05-12 | 2011-11-14 | Method for screening osteopontin inhibitor and inhibitor obtained from the method |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010131826A1 true WO2010131826A1 (ko) | 2010-11-18 |
Family
ID=43085183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2009/007114 WO2010131826A1 (ko) | 2009-05-12 | 2009-12-01 | 오스테오폰틴 억제제 스크리닝 방법 및 그에 따른 억제제 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20120264942A1 (ko) |
EP (1) | EP2431738A4 (ko) |
JP (1) | JP2012526983A (ko) |
KR (1) | KR20120030351A (ko) |
WO (1) | WO2010131826A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016036165A1 (ko) * | 2014-09-05 | 2016-03-10 | 서울대학교 산학협력단 | 오스테오폰틴 단백질의 발현 또는 활성 억제제를 유효성분으로 함유하는 암치료용 약학적 조성물 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9513294B2 (en) | 2012-12-26 | 2016-12-06 | National University Of Singapore | Megastokes amino-triazolyl-BODIPY compounds and applications to live neuron staining and human serum albumin FA1 drug site probing |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020188962A1 (en) * | 1998-06-30 | 2002-12-12 | Denhardt David T. | Osteopontin knock-out mouse and methods of use thereof |
WO2003007794A2 (en) * | 2001-07-20 | 2003-01-30 | Children's Medical Center Corporation | Invasion complex and methods of targeting |
US20050250162A1 (en) * | 2002-03-19 | 2005-11-10 | Kowa Co., Ltd. | Preventives/remedies for myeloma tumor and method of diagnosing the same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60131525T2 (de) * | 2000-03-23 | 2008-09-25 | Glaxo Group Ltd., Greenford | Verfahren zum screening von inhibitoren für osteopontin |
NZ528483A (en) * | 2001-04-05 | 2008-03-28 | Astellas Pharma Inc | Anti-osteopontin antibody and use thereof |
-
2009
- 2009-12-01 EP EP09844700.6A patent/EP2431738A4/en not_active Withdrawn
- 2009-12-01 WO PCT/KR2009/007114 patent/WO2010131826A1/ko active Application Filing
- 2009-12-01 KR KR1020117026856A patent/KR20120030351A/ko not_active Application Discontinuation
- 2009-12-01 JP JP2012510731A patent/JP2012526983A/ja not_active Withdrawn
-
2011
- 2011-11-14 US US13/296,049 patent/US20120264942A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020188962A1 (en) * | 1998-06-30 | 2002-12-12 | Denhardt David T. | Osteopontin knock-out mouse and methods of use thereof |
WO2003007794A2 (en) * | 2001-07-20 | 2003-01-30 | Children's Medical Center Corporation | Invasion complex and methods of targeting |
US20050250162A1 (en) * | 2002-03-19 | 2005-11-10 | Kowa Co., Ltd. | Preventives/remedies for myeloma tumor and method of diagnosing the same |
US20070142281A1 (en) * | 2002-03-19 | 2007-06-21 | Kowa Co., Ltd. | Preventives/remedies for myeloma tumor and method for diagnosing the same |
Non-Patent Citations (11)
Title |
---|
BOYLE WJ. ET AL., NATURE, vol. 423, 2003, pages 337 - 42 |
CATHY J. AITKEN. ET AL., CELL. BIOCHEM, vol. 93, 2004, pages 896 - 903 |
DANA D. HU. ET AL., JBC, vol. 28, 1995, pages 9917 - 9925 |
GIACHELLI C. M. ET AL., MATRIX BIOLOGY, vol. 19, 2000, pages 615 - 622 |
GIACHELLI, C. M ET AL., TRENDS CARDIOVASC MED, vol. 3, 1995, pages 88 - 95 |
HIROYUKI YOSHITAKE ET AL., PNAS., vol. 96, 1999, pages 8156 - 8160 |
ICHIRO NAKAMURA ET AL., J BONE MINER METAB, vol. 25, 2007, pages 337 - 344 |
KENJI YUMOTO ET AL., PNAS, vol. 99, 2002, pages 4556 - 4561 |
KHAN SA. ET AL., MOL. BIOL. CELL, vol. 85, pages 728 - 736 |
ROSS, F.P. ET AL., J. BIOL. CHEM., vol. 268, 1993, pages 9901 - 9907 |
See also references of EP2431738A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016036165A1 (ko) * | 2014-09-05 | 2016-03-10 | 서울대학교 산학협력단 | 오스테오폰틴 단백질의 발현 또는 활성 억제제를 유효성분으로 함유하는 암치료용 약학적 조성물 |
Also Published As
Publication number | Publication date |
---|---|
JP2012526983A (ja) | 2012-11-01 |
KR20120030351A (ko) | 2012-03-28 |
EP2431738A1 (en) | 2012-03-21 |
US20120264942A1 (en) | 2012-10-18 |
EP2431738A4 (en) | 2013-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8680070B2 (en) | Medical implants containing adenosine receptor agonists and methods for inhibitiing medical implant loosening | |
US20150216832A1 (en) | Method for treating inflammation by administering a compound which binds ldl-receptor-related protein (lrp) ligand binding domain | |
Burt et al. | Localization of adrenergic and neuropeptide tyrosine-containing nerves in the mammalian liver | |
Cooper et al. | Effects of the β-carbolines, harmane and pinoline, on insulin secretion from isolated human islets of Langerhans | |
JP2005516054A (ja) | コネキシンヘミチャンネルを調節する組成物及びその方法 | |
Cao et al. | Met5-enkephalin-induced cardioprotection occurs via transactivation of EGFR and activation of PI3K | |
US20180296632A1 (en) | Use of peptides to stimulate the immune system | |
WO2010131826A1 (ko) | 오스테오폰틴 억제제 스크리닝 방법 및 그에 따른 억제제 | |
US20130324595A1 (en) | C-glucosidic ellagitannin compounds for use for altering the supramolecular arrangement of actin and for the treatment of osteoporosis, cancer, bacterial infection and viral infection | |
WO2011025086A1 (ko) | 레바미피드를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물 | |
KR20110134654A (ko) | 신규한 오스테오폰틴 억제제 스크리닝 방법 및 그에 따른 억제제 | |
Ratti et al. | Picotamide, an antithromboxane agent, inhibits the migration and proliferation of arterial myocytes | |
US9381245B2 (en) | Methods for inhibiting osteolysis | |
US20180055868A1 (en) | Methods and compositions for stimulating bone regeneration | |
WO2021187787A1 (ko) | Plk-1 억제제 탐색 방법 및 그에 의해서 탐색된 억제제 및 그 용도 | |
WO2003080103A1 (en) | Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents | |
WO2012133960A1 (ko) | 디펩티딜 펩티데이즈 포에 대한 억제제 | |
US20120087980A1 (en) | Stimulation of neuroregeneration by flavonoid glycosides | |
KR101135026B1 (ko) | 디펩티딜 펩티데이즈 포에 대한 억제제 스크리닝 방법 및 그 억제 제 | |
AU1110600A (en) | Methods for regulating bone formation | |
WO2018147516A1 (ko) | 홍합단백질 유래 펩타이드를 유효성분으로 포함하는 골질환의 예방 또는 치료용 조성물 | |
KR101176041B1 (ko) | 디펩티딜 펩티데이즈 포에 대한 억제제 스크리닝 방법 및 그 억제 제 | |
US20030229137A1 (en) | Methods of inhibiting osteoclast activity | |
AU2001278073A1 (en) | Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplant rejection | |
Ong et al. | Drug Repurposing of Clinically Approved Drugs to Target Epithelial-mesenchymal Transition Using Molecular Docking Approach. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09844700 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20117026856 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012510731 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009844700 Country of ref document: EP |